Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 407-411, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-690976
ABSTRACT
<p><b>OBJECTIVE</b>To explore the individualized treatment for patient with chronic phase chronic myeloid leukemia(CML-CP).</p><p><b>METHODS</b>The clinical data and treatment process of one CML-CP patient which intolerated to nilotinib were analyzed.</p><p><b>RESULTS</b>Nilotinib was given to the patient once the diagnosis of CML-CP was set. Although major molecular remission (MMR) and complete cytogenetic remission (CCyR) were obtained during treatment for 3 months, a grade 3-4 hepatotoxicity appeared in the course of treatment.With drug reduction and symptomatic treatment, nilotinib was discontinued after 3 withdrawals and replaced with imatinib in January 11, 2015. The patients achieved MMR and CCyR at 7 months after imatinib replacement. At present, the patient tolerated well without any adverse events.</p><p><b>CONCLUSION</b>Imatinib can be used as a second-line treatment drug for CML patients who was intolerant to nilotinib, and with less adverts, good effect and so on.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Pyrimidines
/
Benzamides
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Treatment Outcome
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
Imatinib Mesylate
/
Antineoplastic Agents
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS